Rhabdoviridae infectious disease

Summary

Rhabdoviridae infectious disease (MONDO:0005944) is a disease and 1 clinical trial. Top therapeutic interventions include rabies vaccine. A subtype of Mononegavirales infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Rhabdoviridae infectious disease
Mondo ID	MONDO:0005944
EFO	EFO:0007469
MeSH	D018353
UMLS	C0206751
MedGen	60221
Is cancer (heuristic)	no

Also known as: infection, Rhabdoviridae · infections, Rhabdoviridae · Rhabdoviridae infection

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Rhabdoviridae infectious disease

Related subtypes (4): respiratory syncytial virus infectious disease, Filoviridae infectious disease, Paramyxoviridae infectious disease, borna virus encephalitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Rabies Immune Globulin	Phase 3
Rabies Vaccine	Phase 3

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04644484	PHASE3	COMPLETED	A Phase III Clinical Study to Evaluate SYN023’s Efficacy and Safety

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RABIES VACCINE	3	1